Will Butler is a Texas native and Boise-based entrepreneur, sales director, and business development leader who specializes in building outbound systems that turn cold markets into predictable revenue.

As the founder of Siro Business Development Firm, Will has led growth initiatives across multiple industries, including SaaS, biotech, insurance, translation, and high-ticket B2C. He helps ambitious companies scale through precision-targeted outbound frameworks that generate measurable results.

His track record includes meetings booked with Hogan Lovells, Kaiser Permanente, Insulet, Moxie Pest Control, Priority Roofing, and more, as well as helping sell into FIGS, NYU, the U.S. Department of Justice, SEIU, and top-20 global litigation firms.

Before founding Siro, Will built and scaled Evolution Academy from $0 to $70K in revenue without paid media by age 21. He grew the brand’s social presence from zero to 38.6K followers in less than six months and generated over 6 million views on a single post before successfully exiting the company.

Will earned his Bachelor of Science in Aviation Management and Operations from Oklahoma State University. In the category of General Aviation and Aeronautics Schools, OSU ranks #5 among 100 schools in the United States (2024, Pilot-Colleges.com). He originally trained as a professional pilot, but after being diagnosed with Type 1 Diabetes at age 22 as a late-stage diagnosis, he was forced to pivot careers. That diagnosis became a defining moment in his life and shaped his mission moving forward.

Mentored by top industry leaders including Nick Rogers, Jake Valentine, and Jason Capital, Will has since facilitated deal origination with the 14th largest law firm worldwide, the 3rd largest healthcare system globally, and leading U.S. contractors ranked #8, #9 and #18.

Through his work at Siro, Will continues to blend data-driven business development with human-centered storytelling. He helps companies scale faster while pursuing his personal mission to increase awareness and accelerate progress toward a cure for Type 1 Diabetes.